Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -46.66% is 39% below its 5-year average of -33.55%, near the low end of its 5-year range (-49.01%–-19.85%).
0.79% below its 12-month average of -46.30%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.44%.
RETURN ON ASSETS (ROA)
-46.66%
RETURN ON ASSETS (ROA) AVG TTM
-46.30%
RETURN ON ASSETS (ROA) AVG 3Y
-40.19%
RETURN ON ASSETS (ROA) AVG 5Y
-33.55%
RETURN ON ASSETS (ROA) AVG 10Y
-27.21%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-0.79%
CURRENT VS 3Y AVG
-16.09%
CURRENT VS 5Y AVG
-39.06%
CURRENT VS 10Y AVG
-71.49%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.85%
median of 100 covered companies
CURRENT VS SECTOR MEDIAN
-1062.06%
vs the sector median at left
Intellia Therapeutics, Inc.
Market Cap
$1.71B
Return on Assets (ROA)
-46.66%
TTM Avg
-46.30%
3Y Avg
-40.19%
5Y Avg
-33.55%
Market Cap
$1.74B
Return on Assets (ROA)
-10.49%
TTM Avg
-13.41%
3Y Avg
-10.26%
5Y Avg
-6.23%
Market Cap
$1.90B
Return on Assets (ROA)
-3.14%
TTM Avg
-22.75%
3Y Avg
-10.43%
5Y Avg
-6.58%
Market Cap
$2.16B
Return on Assets (ROA)
-42.79%
TTM Avg
-37.88%
3Y Avg
-40.02%
5Y Avg
-36.63%
Market Cap
$1.00B
Return on Assets (ROA)
-6.43%
TTM Avg
-17.46%
3Y Avg
-82.63%
5Y Avg
-55.94%
Market Cap
$2.52B
Return on Assets (ROA)
-6.16%
TTM Avg
-19.77%
3Y Avg
-17.54%
5Y Avg
-23.06%
Market Cap
$2.76B
Return on Assets (ROA)
10.36%
TTM Avg
11.11%
3Y Avg
1.40%
5Y Avg
-7.68%
Market Cap
$474.59M
Return on Assets (ROA)
-3.84%
TTM Avg
-6.38%
3Y Avg
-6.57%
5Y Avg
-4.38%
Market Cap
$458.62M
Return on Assets (ROA)
4.30%
TTM Avg
13.65%
3Y Avg
19.24%
5Y Avg
21.45%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | $1.71B | -46.66% | -46.30% | -40.19% | -33.55% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | -10.49% | -13.41% | -10.26% | -6.23% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.90B | -3.14% | -22.75% | -10.43% | -6.58% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | -42.79% | -37.88% | -40.02% | -36.63% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | -6.43% | -17.46% | -82.63% | -55.94% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | -6.16% | -19.77% | -17.54% | -23.06% |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 10.36% | 11.11% | 1.40% | -7.68% |
| NeoGenomics, Inc. (NEO)vs › | $474.59M | -3.84% | -6.38% | -6.57% | -4.38% |
| NRC Health (NRC)vs › | $458.62M | 4.30% | 13.65% | 19.24% | 21.45% |
| Shoulder Innovations, Inc. (SI)vs › | $394.23M | -23.05% | -30.00% | -27.77% | -27.77% |
ROA
-46.7%
ROE
-55.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -49.01% |
| 2024-12-31 | -43.58% |
| 2023-12-31 | -36.99% |
| 2022-12-31 | -31.19% |
| 2021-12-31 | -20.70% |
| 2020-12-31 | -19.85% |
| 2019-12-31 | -29.78% |
| 2018-12-31 | -24.57% |
| 2017-12-31 | -17.95% |
| 2016-12-31 | -10.58% |
| 2015-12-31 | -15.09% |
| 2014-12-31 | -133.80% |
